These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 25039318)

  • 41. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function.
    Alba M; Ahrén B; Inzucchi SE; Guan Y; Mallick M; Xu L; O'Neill EA; Williams-Herman DE; Kaufman KD; Goldstein BJ
    Diabetes Obes Metab; 2013 Dec; 15(12):1101-10. PubMed ID: 23782502
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes.
    Derosa G; Franzetti IG; Querci F; Carbone A; Ciccarelli L; Piccinni MN; Fogari E; Maffioli P
    Diabet Med; 2012 Dec; 29(12):1515-23. PubMed ID: 22540883
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Development and assessment of the disposition index based on the oral glucose tolerance test in subjects with different glycaemic status.
    Santos JL; Yévenes I; Cataldo LR; Morales M; Galgani J; Arancibia C; Vega J; Olmos P; Flores M; Valderas JP; Pollak F
    J Physiol Biochem; 2016 Jun; 72(2):121-31. PubMed ID: 26660757
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of single-dose DPP-4 inhibitor sitagliptin on β-cell function and incretin hormone secretion after meal ingestion in healthy volunteers and drug-naïve, well-controlled type 2 diabetes subjects.
    Alsalim W; Göransson O; Carr RD; Bizzotto R; Tura A; Pacini G; Mari A; Ahrén B
    Diabetes Obes Metab; 2018 Apr; 20(4):1080-1085. PubMed ID: 29227575
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Relationship between serum secreted frizzled-related protein 4 levels and the first-phase of glucose-stimulated insulin secretion in individuals with different glucose tolerance.
    Liu F; Qu H; Li Y; Tang Q; Yang Z; Wang H; Deng H
    Endocr J; 2015; 62(8):733-40. PubMed ID: 26041556
    [TBL] [Abstract][Full Text] [Related]  

  • 46. β-Cell function in postmenopausal women with isolated post-challenge hyperglycemia.
    Hwu CM; Lin YC; Lin KH
    J Diabetes; 2018 Feb; 10(2):158-165. PubMed ID: 28544644
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Native Oxyntomodulin Has Significant Glucoregulatory Effects Independent of Weight Loss in Obese Humans With and Without Type 2 Diabetes.
    Shankar SS; Shankar RR; Mixson LA; Miller DL; Pramanik B; O'Dowd AK; Williams DM; Frederick CB; Beals CR; Stoch SA; Steinberg HO; Kelley DE
    Diabetes; 2018 Jun; 67(6):1105-1112. PubMed ID: 29545266
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Worse pancreatic β-cell function and better insulin sensitivity in older Chinese without diabetes.
    Xiao J; Weng J; Ji L; Jia W; Lu J; Shan Z; Liu J; Tian H; Ji Q; Yang Z; Yang W;
    J Gerontol A Biol Sci Med Sci; 2014 Apr; 69(4):463-70. PubMed ID: 23974206
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Association of soluble apoptotic markers with impaired left ventricular deformation in patients with rheumatoid arthritis. Effects of inhibition of interleukin-1 activity by anakinra.
    Ikonomidis I; Tzortzis S; Lekakis J; Paraskevaidis I; Dasou P; Parissis J; Nikolaou M; Markantonis SL; Katsimbri P; Skarantavos G; Andreadou I; Anastasiou-Nana M
    Thromb Haemost; 2011 Nov; 106(5):959-67. PubMed ID: 21947196
    [TBL] [Abstract][Full Text] [Related]  

  • 50. One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus.
    van Asseldonk EJ; van Poppel PC; Ballak DB; Stienstra R; Netea MG; Tack CJ
    Clin Immunol; 2015 Oct; 160(2):155-62. PubMed ID: 26073226
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch acarbose intervention study in persons with impaired glucose tolerance (DAISI).
    Nijpels G; Boorsma W; Dekker JM; Kostense PJ; Bouter LM; Heine RJ
    Diabetes Metab Res Rev; 2008; 24(8):611-6. PubMed ID: 18756586
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Elevated 1-hour postload plasma glucose levels identify subjects with normal glucose tolerance but impaired β-cell function, insulin resistance, and worse cardiovascular risk profile: the GENFIEV study.
    Bianchi C; Miccoli R; Trombetta M; Giorgino F; Frontoni S; Faloia E; Marchesini G; Dolci MA; Cavalot F; Cavallo G; Leonetti F; Bonadonna RC; Del Prato S;
    J Clin Endocrinol Metab; 2013 May; 98(5):2100-5. PubMed ID: 23539736
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of pioglitazone on insulin secretion in patients with both impaired fasting glucose and impaired glucose tolerance.
    González-Ortiz M; Hernández-Salazar E; Kam-Ramos AM; Martínez-Abundis E
    Diabetes Res Clin Pract; 2007 Jan; 75(1):115-8. PubMed ID: 16781793
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A multiple-ascending-dose study to evaluate safety, pharmacokinetics, and pharmacodynamics of a novel GPR40 agonist, TAK-875, in subjects with type 2 diabetes.
    Leifke E; Naik H; Wu J; Viswanathan P; Demanno D; Kipnes M; Vakilynejad M
    Clin Pharmacol Ther; 2012 Jul; 92(1):29-39. PubMed ID: 22669289
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preliminary studies related to anti-interleukin-1β therapy in children with newly diagnosed type 1 diabetes.
    Sumpter KM; Adhikari S; Grishman EK; White PC
    Pediatr Diabetes; 2011 Nov; 12(7):656-67. PubMed ID: 21518168
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus.
    Donath MY; Mandrup-Poulsen T
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):240-1. PubMed ID: 18317479
    [No Abstract]   [Full Text] [Related]  

  • 57. The effect of chromium on inflammatory markers, 1st and 2nd phase insulin secretion in type 2 diabetes.
    Chen YL; Lin JD; Hsia TL; Mao FC; Hsu CH; Pei D
    Eur J Nutr; 2014 Feb; 53(1):127-33. PubMed ID: 23494740
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Diabetes treatment--bridging the divide.
    Rother KI
    N Engl J Med; 2007 Apr; 356(15):1499-501. PubMed ID: 17429082
    [No Abstract]   [Full Text] [Related]  

  • 59. IL-1 receptor antagonist reduces endotoxin-induced airway inflammation in healthy volunteers.
    Hernandez ML; Mills K; Almond M; Todoric K; Aleman MM; Zhang H; Zhou H; Peden DB
    J Allergy Clin Immunol; 2015 Feb; 135(2):379-85. PubMed ID: 25195169
    [TBL] [Abstract][Full Text] [Related]  

  • 60. HOMA-beta in the UKPDS and ADOPT. Is the natural history of type 2 diabetes characterised by a progressive and inexorable loss of insulin secretory function? Maybe? Maybe not?
    Reaven GM
    Diab Vasc Dis Res; 2009 Apr; 6(2):133-8. PubMed ID: 20368203
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.